3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Nasopharyngeal Carcinoma
7
Breast Neoplasms
6
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Neoplasm Metastasis
2
Locally Advanced Rectal Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Adrenocortical Carcinoma
2
Unresectable Gallbladder Cancer
1
Turcot syndrome
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Non Squamous Non Small Cell Lung Cancer
1
Nasopharyngeal Neoplasms
1
Multiple Primary Lung Cancer
1
Melanoma
1
Locally Advanced or Metastatic Solid Tumors
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Her-2 Negative Breast Cancer
1
Interventions
Cyclophosphamide
8
fludarabine
6
cabozantinib
5
Temozolomide
4
Doxorubicin
4
Zoledronic Acid
3
X-Rays
3
Vincristine
3
Methotrexate
3
Ifosfamide
3
Gemcitabine
3
Cisplatin
3
irinotecan sucrosofate
2
atezolizumab
2
Surgical Procedures, Operative
2
Sunitinib
2
Specimen Handling
2
Radiosurgery
2
Phantoms, Imaging
2
Mesna
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Eflornithine
2
Disulfiram
2
Biopsy
2
vactosertib
1
trilaciclib
1
trametinib
1
talazoparib
1
surufatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Osteosarcoma
×
camrelizumab
×
Clear all
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled